"uuid:ID","instanceType","id","rationale","versionIdentifier"
"8e37bb1d-3f7e-45d9-b6e8-a5f57c6a539b","StudyVersion","StudyVersion_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","2"
